Last reviewed · How we verify
NCT03700177
Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block
Phase 4 trial testing Dexamethasone in Effect of Drugs in 60 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Medical University Innsbruck |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 February 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Dexamethasone (dexamethasone) — full drug profile →
- Placebo
- Ropivacaine Injection [Naropin] — full drug profile →
Conditions studied
- Effect of Drugs — all drugs for Effect of Drugs →
- Breast Pain — all drugs for Breast Pain →
- Anesthesia, Local — all drugs for Anesthesia, Local →
Sponsor
Medical University Innsbruck
Who can join
Adults 18 to 90, female only, with Effect of Drugs or Breast Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To find out if dexamethasone used as adjuvant to ropivacaine, a long-lasting local anesthetic, prolongs the duration of modified pectoral nerve block in women undergoing breast surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03700177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dexamethasone
Trials testing the same drug.
- NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Other Medical University Innsbruck trials
Trials by the same sponsor.
- NCT07408726 — Monoaxial vs. Polyaxial Percutaneous Hybrid Stabilization · NA · not yet recruiting
- NCT07101107 — Socio-cognitive and Biological Responses to Maltreatment · not yet recruiting
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07434648 — Comparison of Mastectomy Expander Trial · NA · not yet recruiting
- NCT07391683 — Telemedically Assisted Optimization for Heart Failure Patients Before Cardiac Surgery to Improve Perioperative Outcome · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03700177 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University Innsbruck
- Last refreshed: 12 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03700177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing